Document is current
Any future updates will be listed below
-
Authors
Joyce, Daniel P.
Berger, Jeffrey S.
Guttmann, Allison
Hasan, Ghadeer
Buyon, Jill P.
Belmont, H. Michael
Salmon, Jane
Askanase, Anca
Bathon, Joan
Geraldino-Pardilla, Laura
Ali, Yousaf
Ginzler, Ellen M.
Putterman, Chaim
Gordon, Caroline
Helmick, Charles G.
Barbour, Kamil E.
Gold, Heather T.
Parton, Hilary
Izmirly, Peter M. http://orcid.org/0000-0001-5445-2182
-
Funding
Funding for this research was provided by:
Centers for Disease Control and Prevention (U01DP006700, U01DP006700, U58/DP002827, U01DP006700)
New York City Department of Health and Mental Hygiene
- License Information
-
More Information
Article History
Received: 21 June 2024
Accepted: 3 September 2024
First Online: 14 September 2024
Declarations
:
: The data used in the manuscript were extracted from medical records under the health surveillance exemption to HIPAA privacy rules [45 CFR § 164.512 (b)] and as authorized by New York City Charter Sect. 556(c) [] and (d) []. As a surveillance study, the creation of the MLSP did not require institutional review board (IRB) approval at CDC, New York City Department of Health and Mental Hygiene (DOHMH), or the New York University Grossman School of Medicine. The DOHMH IRB approved secondary analyses, including those reported herein, on a de-identified dataset (NYC DOHMH IRB no. 16–147).
: Not applicable.
: PMI - consulting fees from GSK, Momenta/Janssen, Hansoh Bio; JPB - consulting fees from Bristol-Myers Squibb, GlaxoSmithKline, Related Sciences LLC, Ventus Therapeutics, Artiva; and CG - consulting fees from Alumis, Amgen, Astra-Zeneca, Sanofi, and UCB.
